Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Glycosylation of immunoglobulin light chains in CAD

Surbhi Sidana • 31 May 2020
Amyloidosis Cold Agglutinin Disease Non-Malignant

In this interview, Surbhi Sidana, MD, of the Mayo Clinic, Stanford, CA, discusses glycosylation of immunoglobulin as it relates to cold agglutinin disease (CAD) and how this can signify a risk for amyloidosis development. In this discussion, glycosylation is evaluated as a diagnostic tool for this indication. This interview was recorded via an online conference call with the Video Journal of Hematological Oncology (VJHemOnc).

More from Surbhi Sidana

1:29
Managing toxicities associated with immunotherapy in multiple myeloma
Surbhi Sidana • 8 Dec 2023
1:43
Ide-cel therapy for multiple myeloma with renal impairment
Surbhi Sidana • 8 Dec 2023
3:09
An overview of the toxicities associated with immunotherapy in multiple myeloma
Surbhi Sidana • 8 Dec 2023
1:59
Real-world outcomes of ide-cel in heavily pre-treated R/R MM
Surbhi Sidana • 8 Dec 2023

Related Videos

2:27
Optimizing the delivery of care for patients with hemoglobinopathies in the UK
Farrukh Shah • 30 Apr 2024
1:06
The importance of shared-decision making when treating infants with hemophilia
Jayashree Motwani • 28 Apr 2024
2:24
Primary prevention against atherosclerosis in patients with hemophilia
Beverley Hunt • 29 Apr 2024
2:40
The safety & efficacy of emicizumab in patients under 18 months with hemophilia A
Eman Hassan • 28 Apr 2024
The content of VJHemOnc is intended for healthcare professionals